Pulmonary hypertension combination therapy may lead to greater disease burden

Patients with pulmonary arterial hypertension (PAH) receiving combination therapy with intravenous (IV) PGI2 may suffer from greater disease burden compared with those receiving monotherapy or combination therapy, excluding IV PGI2.

Researchers from Massachusetts General Hospital and Novartis Pharma AG in Switzerland performed statistical tests on 446 patients with PAH, of which (a) 337 were receiving monotherapy; (b) 88 were receiving non-IV PGI2 combination therapy; and (c) 21 were receiving IV PGI2 .

Results showed that pulmonary vascular resistance, mean number of PAH-related hospitalizations, and dyspnea scores were highest in those treated with IV PGI2.

This study was presented during CHEST 2012, the annual meeting of the , held October 20 – 25, in Atlanta, Georgia.

add to favorites email to friend print save as pdf

Related Stories

Gene therapy may be effective in treating PAH

May 19, 2010

Gene therapy has been shown to have positive effects in rat models of pulmonary arterial hypertension (PAH), according to researchers at the University of Adelaide in Australia.

Recommended for you

Impact of whooping cough vaccination revealed

12 hours ago

The most comprehensive study to date of the family of bacteria that causes whooping cough points to more effective vaccine strategies and reveals surprising findings about the bacteria's origin and evolution. The new results ...

User comments